Finally, a deals database built specifically for biopharma.
DealForma stands out as the best in biopharma deal data with its comprehensive coverage of biotech and pharma licensing and funding transactions by providing a superior experience when it comes to deal terms. We focus on delivering high-quality deal data so you can have confidence that you are getting complete and accurate information for your biopharma business development deal comps and benchmark research.
DealForma provides the most extensive coverage of biopharmaceutical transactions, including licensing deals, asset purchases, mergers, acquisitions, research partnerships, and funding rounds, ensuring you have access to a vast repository of relevant data.
With granular and relevant filters, DealForma allows you to delve into transaction details, track trends, and gain valuable insights into deal structures, valuations, therapeutic areas, and key players, enabling strategic planning, market analysis, and competitive intelligence.
Advanced Deal Monitoring
Business developers are switching to DealForma for its advanced deal monitoring capabilities. The platform enables you to set up alerts for specific criteria, such as target companies, indications, or modalities so you stay informed about the latest developments and deal opportunities.
Compare DealForma vs. PitchBook
Comparison based on customer feedback and public information gathered January 2024 to the best of our knowledge. We understand the world is constantly changing, so if you see we missed a feature or made a mistake, let us know.
DealForma vs. PitchBook
PitchBook is widely recognized for its expertise in venture capital analysis and company-provided valuations across various industries. DealForma is focused on biopharma, so deal comps, therapeutic areas, modalities, discovery and clinical stages, and targets are intentionally curated to give you the most relevant data on biotech and pharma business development, licensing, and funding. DealForma is built for biopharma, from the data to the attached sources and contracts.
Why are biopharma and finance companies switching to DealForma?
"DealForma is a Better Deal Database"
We keep hearing from business developers who have tried other databases and DealForma. They are switching to DealForma because of the deal-focused filters and the ability to quickly pull relevant deal comps knowing the content is high-quality. This saves them time when creating reports because the information is verified and up-to-date.
Intuitive, Modern Interface
You know that biopharma business development is full of complex terminology. But you shouldn’t have to remember how a database codes things. DealForma designed its platform from the ground up to make finding the most relevant information fast and easy. DealForma’s granular filters give you the confidence in working with the right data.
Intentional Biopharma Deal Curation
Analysts at DealForma have experience reading thousands of deal and funding announcements and company filings. Teams assigned to each segment look for key terms to separate out from a noisy news flow. And they do this manually, every day, so you can quickly filter through decades of carefully curated, relevant transaction profiles.
Included Analyst Support
DealForma goes beyond a mere database by providing you 20 hours of analyst time per year included with your subscription for you to leverage the expertise of skilled professionals to assist you in data interpretation, perform custom analyses, and provide valuable insights tailored to specific business needs.
The breadth and quality of information in DealForma has saved our team countless hours over other data sources. The focus on customers also sets them apart. Whether it’s a quick question or a custom project, we get the right people to talk to fast.
I like DealForma’s comprehensive coverage of the life sciences industry. The intuitive search functions allow me to quickly extract deal benchmarks and other insights, which are useful in helping me evaluate potential opportunities.
DealForma is an exceptional and intuitive platform with reliable data that has saved us countless hours. The support team is quick to respond, and they go above and beyond to make sure we get what we need whether it is a quick question or a more intensive project.
Best product in the business!
I’ve been reviewing data on biopharma business trends for 16 years now, and no one does the number crunching better than Chris Dokomajilar at DealForma. I’ve seen the data pressure tested repeatedly, and it is solid. We’re proud to have him contribute regular pieces to Endpoints News.
Drug Sales Figures
All of this by stage, disease indication, modality, target...